NDI-Lyso

Overview

NDI-Lyso is a lysosome-targeted anticancer agent that induces the formation of rigid long fibers in cancer cell lysosomes through an enzyme-instructed self-assembly (EISA) mechanism catalyzed by cathepsin B . This process triggers lysosomal swelling, membrane permeabilization ( LMP ), and membrane disruption, ultimately leading to cancer cell apoptosis via a non-classical caspase-independent pathway . NDI-Lyso exhibits significant selective anticancer activity in various cancer cell lines and drug-resistant cancer cells ( IC 50 ~10 μM) while showing low toxicity to normal cells ( IC 50 > 60 μM).

Application

Products | Products > Peptides | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-P10669
• CAS No.: 2999646-19-2
• Molecular Formula: C71H100N22O13
• Molecular Weight: 1469.69
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source